1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Saudi Arabia Pharmaceuticals and Healthcare Report Q2 2016

Saudi Arabia Pharmaceuticals and Healthcare Report Q2 2016

  • March 2016
  • -
  • Business Monitor International
  • -
  • 94 pages

Includes 3 FREE quarterly updates

BMI View: High per capita spending on pharmaceuticals and a rising burden of chronic diseases willsupport long-term pharmaceutical growth in Saudi Arabia. However, a prolonged period of subdued oilprices may see Saudi Arabia cut back on high value drug spending - posing a risk to innovativedrugmakers. Our outlook for the country's healthcare sector is a positive one. As such, the government'sfocus on healthcare will remain a priority, owing to the sensitive nature of the sector and its politicalimportance. However, cost-containment measures will be encouraged, and over the long-term, the privatesector will play an increasingly important role in the provision of healthcare in Saudi Arabia.

Headline Expenditure Projections

- Pharmaceuticals: SAR31.75bn (USD8.46bn) in 2015 to SAR35.32bn (USD9.42bn) in 2016; +11.3% inboth local currency and US dollar terms. Forecast unchanged from Q116.

- Healthcare: SAR113.11bn (USD30.16bn) in 2015 to SAR123.31bn (USD32.88bn) in 2016; +9.0% inboth local currency and US dollar terms. Forecast in line with Q116.

Table Of Contents

Saudi Arabia Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Saudi Arabia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Saudi Arabia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 23
OTC Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Saudi Arabia 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Saudi Arabia 2014-2020) 29
Industry Risk Reward Index 30
Middle East and Africa Risk/Reward Index - Q2 2016 30
Saudi Arabia Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Intellectual Property Issues 41
Pricing Regime 43
Reimbursement Regime 46
Market Overview 47
Healthcare Sector 48
Table: Healthcare Resources (Saudi Arabia 2010-2015) 53
Table: Healthcare Personnel (Saudi Arabia 2010-2015) 53
Table: Healthcare Activity (Saudi Arabia 2010-2015) 54
Research and Development 54
Clinical Trials 56
Epidemiology 57
Competitive Landscape 60
Research-Based Industry 60
Table: Multinational Market Activity 63
Generic Drugmakers 64
Pharmaceutical Distribution 65
Pharmaceutical Retail Sector 66
Company Profile 68
GlaxoSmithKline 68
Sanofi 71
SPIMACO 74
TABUK Pharmaceutical Manufacturing 78
Novartis 81
Demographic Forecast 83
Demographic Outlook 83
Table: Population Headline Indicators (Saudi Arabia 1990-2025) 84
Table: Key Population Ratios (Saudi Arabia 1990-2025) 84
Table: Urban/Rural Population and Life Expectancy (Saudi Arabia 1990-2025) 85
Table: Population By Age Group (Saudi Arabia 1990-2025) 85
Table: Population By Age Group % (Saudi Arabia 1990-2025) 86
Glossary 88
Methodology 90
Pharmaceutical Expenditure Forecast Model 90
Healthcare Expenditure Forecast Model 90
Notes On Methodology 91
Risk/Reward Index Methodology 92
Index Overview 93
Table: Pharmaceutical Risk/Reward Index Indicators 93
Indicator Weightings 94

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.